Peter Hunt, MD, of UC San Diego School of Medicine, presents "Immune Activation in Treated HIV infection," at AIDS Clinical Rounds on September 12, 2014
Sara Gianella Weibel, M.D., of UC San Diego Department of Medicine, presents "Inflammation Persists Even During HIV Therapy" for AIDS Clinical Rounds at UC San Diego
Cardiovascular Disease in HIV-Infected Patients.Predict It and Prevent It.2015Hivlife Info
In this downloadable slideset, Priscilla Y. Hsue, MD, and David A. Wohl, MD, discuss data on using traditional and newer markers and modalities to predict and prevent cardiovascular disease in HIV-infected patients.
Format: Microsoft PowerPoint (.ppt)
File size: 3.21 MB
Date posted: 7/16/2015
HIV and Cardiovascular Disease.How Worried Should We Be ? 2015Hivlife Info
In this downloadable slideset, David A. Wohl, MD, reviews the association between HIV and cardiovascular disease, including potential contributing factors and best practices in prevention.
Format: Microsoft PowerPoint (.ppt)
File size: 5.01 MB
Date posted: 6/26/2015
Peter Hunt, MD, of UC San Diego School of Medicine, presents "Immune Activation in Treated HIV infection," at AIDS Clinical Rounds on September 12, 2014
Sara Gianella Weibel, M.D., of UC San Diego Department of Medicine, presents "Inflammation Persists Even During HIV Therapy" for AIDS Clinical Rounds at UC San Diego
Cardiovascular Disease in HIV-Infected Patients.Predict It and Prevent It.2015Hivlife Info
In this downloadable slideset, Priscilla Y. Hsue, MD, and David A. Wohl, MD, discuss data on using traditional and newer markers and modalities to predict and prevent cardiovascular disease in HIV-infected patients.
Format: Microsoft PowerPoint (.ppt)
File size: 3.21 MB
Date posted: 7/16/2015
HIV and Cardiovascular Disease.How Worried Should We Be ? 2015Hivlife Info
In this downloadable slideset, David A. Wohl, MD, reviews the association between HIV and cardiovascular disease, including potential contributing factors and best practices in prevention.
Format: Microsoft PowerPoint (.ppt)
File size: 5.01 MB
Date posted: 6/26/2015
Contemporary Management of HIV.How Common Comorbidities Affect ART Management...hivlifeinfo
In this downloadable slideset, expert faculty review key data and offer important guidance on managing HIV treatment in patients with frequently encountered comorbidities, including cardiovascular disease, osteopenia, and HCV coinfection.
Format: Microsoft PowerPoint (.ppt)
File size: 2.27 MB
Date posted: 2/12/2018
With improvement in the care available for HIV patients since the mid 1990s most HIV patients are living longer. Patients with HIV are now being afflicted with conditions associated with aging including atheroscerotic heart disease. This presentation reviews the current data on coronary artery disease in HIV patients and discusses the management and prevention of these conditions in this population.
Cathy Logan, MD, of the UC San Diego AntiViral Research Center, presents "Solid Organ Transplantation and HIV" at AIDS Clinical Rounds on August 29, 2014
Современное лечение ВИЧ : лечение возрастных пациентов.2017/Contemporary Management of HIV. Management of Aging Patients.2017
In this downloadable slideset, Edgar Turner Overton, MD, and Program Director Joseph J. Eron, Jr., MD, review key data on managing aging patients with HIV.
Source: Contemporary Management of HIV
Date Posted: 4/24/2017
Cardiomyopathy in HIV patients has been shown to progress faster than idiopathic Dilated Cardiomyopathy in the HIV negative population. It is therefore important to recognize this condition early in this population and manage it appropriately. Studies need to be done to validate the current therapy for cardiomyopathy in this population since it is still unclear that LV dysfunction in this population responds in a similar fashion as in HIV negative patients with Dilated Cardiomyopathy
Топ достижений лечения ВИЧ в 2017 г / Top Advances in ART for 2017hivlifeinfo
Top Advances in ART for 2017
In this downloadable slideset, Joel E. Gallant, MD, MPH, provides a comprehensive update on ART management.
Format: Microsoft PowerPoint (.ppt)
File size: 579 KB
Date posted: 3/29/2017
Современное лечение ВИЧ: АРТ у пациентов с сопутствующими заболеваниями.Conte...hivlifeinfo
Современное лечение ВИЧ:АРТ у пациентов с сопутствующими заболеваниями.//Contemporary Management of HIV. Managing ART in HIV-Infected Patients With Common Comorbidities. 2016
In this downloadable slideset, David A. Wohl, MD, and Program Director Eric S. Daar, MD, review key data and optimal approaches for managing ART in the context of common comorbidities.
Format: Microsoft PowerPoint (.ppt)
File size: 3.51 MB
HIV Transplant Case Report, Transplant Outcomes in Clinical Trials, and Organ Availability in High Risk Donors
Katya Prakash
03/15/2019
UCSD HIV & Global Health Rounds
Contemporary Management of HIV.How Aging Affects ART Management.2018hivlifeinfo
In this downloadable slideset, Expert Faculty review key data on managing aging patients with HIV.
Format: Microsoft PowerPoint (.ppt)
File size: 720 KB
Date posted: 3/7/2018
In this downloadable slideset, expert faculty members Andrew Carr, MBBS, MD, FRACP, FRCPA; Daniel R. Kuritzkes, MD; and Ian M. Sanne, MBBCH, FCP(SA), review key studies presented at the 2016 International AIDS Conference.
Format: Microsoft PowerPoint (.ppt)
File size: 1.28 MB
Date posted: 8/5/2016
Современное лечение ВИЧ: когда начинать, чем начинать. Contemporary Managemen...hivlifeinfo
.Contemporary Management of HIV. When to Start, What to Start.2016/Современное лечение ВИЧ: когда начинать, чем начинать.
In this downloadable slideset, Daniel R. Kuritzkes, MD, and Program Director Eric S. Daar, MD review key data and optimal approaches for first-line ART with contemporary HIV regimens.
Format: Microsoft PowerPoint (.ppt)
File size: 2.53 MB
Date posted: 2/9/2016
Contemporary Management of HIV.How Common Comorbidities Affect ART Management...hivlifeinfo
In this downloadable slideset, expert faculty review key data and offer important guidance on managing HIV treatment in patients with frequently encountered comorbidities, including cardiovascular disease, osteopenia, and HCV coinfection.
Format: Microsoft PowerPoint (.ppt)
File size: 2.27 MB
Date posted: 2/12/2018
With improvement in the care available for HIV patients since the mid 1990s most HIV patients are living longer. Patients with HIV are now being afflicted with conditions associated with aging including atheroscerotic heart disease. This presentation reviews the current data on coronary artery disease in HIV patients and discusses the management and prevention of these conditions in this population.
Cathy Logan, MD, of the UC San Diego AntiViral Research Center, presents "Solid Organ Transplantation and HIV" at AIDS Clinical Rounds on August 29, 2014
Современное лечение ВИЧ : лечение возрастных пациентов.2017/Contemporary Management of HIV. Management of Aging Patients.2017
In this downloadable slideset, Edgar Turner Overton, MD, and Program Director Joseph J. Eron, Jr., MD, review key data on managing aging patients with HIV.
Source: Contemporary Management of HIV
Date Posted: 4/24/2017
Cardiomyopathy in HIV patients has been shown to progress faster than idiopathic Dilated Cardiomyopathy in the HIV negative population. It is therefore important to recognize this condition early in this population and manage it appropriately. Studies need to be done to validate the current therapy for cardiomyopathy in this population since it is still unclear that LV dysfunction in this population responds in a similar fashion as in HIV negative patients with Dilated Cardiomyopathy
Топ достижений лечения ВИЧ в 2017 г / Top Advances in ART for 2017hivlifeinfo
Top Advances in ART for 2017
In this downloadable slideset, Joel E. Gallant, MD, MPH, provides a comprehensive update on ART management.
Format: Microsoft PowerPoint (.ppt)
File size: 579 KB
Date posted: 3/29/2017
Современное лечение ВИЧ: АРТ у пациентов с сопутствующими заболеваниями.Conte...hivlifeinfo
Современное лечение ВИЧ:АРТ у пациентов с сопутствующими заболеваниями.//Contemporary Management of HIV. Managing ART in HIV-Infected Patients With Common Comorbidities. 2016
In this downloadable slideset, David A. Wohl, MD, and Program Director Eric S. Daar, MD, review key data and optimal approaches for managing ART in the context of common comorbidities.
Format: Microsoft PowerPoint (.ppt)
File size: 3.51 MB
HIV Transplant Case Report, Transplant Outcomes in Clinical Trials, and Organ Availability in High Risk Donors
Katya Prakash
03/15/2019
UCSD HIV & Global Health Rounds
Contemporary Management of HIV.How Aging Affects ART Management.2018hivlifeinfo
In this downloadable slideset, Expert Faculty review key data on managing aging patients with HIV.
Format: Microsoft PowerPoint (.ppt)
File size: 720 KB
Date posted: 3/7/2018
In this downloadable slideset, expert faculty members Andrew Carr, MBBS, MD, FRACP, FRCPA; Daniel R. Kuritzkes, MD; and Ian M. Sanne, MBBCH, FCP(SA), review key studies presented at the 2016 International AIDS Conference.
Format: Microsoft PowerPoint (.ppt)
File size: 1.28 MB
Date posted: 8/5/2016
Современное лечение ВИЧ: когда начинать, чем начинать. Contemporary Managemen...hivlifeinfo
.Contemporary Management of HIV. When to Start, What to Start.2016/Современное лечение ВИЧ: когда начинать, чем начинать.
In this downloadable slideset, Daniel R. Kuritzkes, MD, and Program Director Eric S. Daar, MD review key data and optimal approaches for first-line ART with contemporary HIV regimens.
Format: Microsoft PowerPoint (.ppt)
File size: 2.53 MB
Date posted: 2/9/2016
10 trucos para no tirar el dinero en Google AdWords. 2018 Manual Google Adwo...Unai Benito
¿Qué es y como funciona Google Adwords?
Primera presentación del curso para la certificación.
Primeros pasos para la realización de campañas de Search, Display. Orientadas tanto a PCS, móviles, Tablets. Campañas SEM nacionales e internacionales.
Manual para la creación y gestión de campañas de Google Adwords. En esta primera presentación nos detallamos en el apartado de las campañas y de su optimización.
En los siguientes manuales de Google Adwords veremos la planificamos de acciones de remarketing para aquellos usuarios que ya han visitado la página Web y queremos ofrecerles alguna oferta especial o recordarles aquellos productos que han visitado los clientes
Optimizamos la eficacia de las campañas de nuestros clientes. Marcamos objetivos de conversión y mejoramos el diseño y experiencia del usuario para conseguir mejores.
www.unaibenito.com
ARV Therapy and the Role of Early Intervention presented by Dr. Rachel Baden, Harvard Medical Faculty Physician at the Fenway Health Center community education conference: An End To AIDS - How A State Bill Can Change Everything hosted by SearchForACure.org, the Fenway Health Center, and the MA Dept. of Public Health
Сердечно-сосудистые заболевания у ВИЧ-инфицированных пациентов : предсказать ...hivlifeinfo
Cardiovascular Disease in HIV-Infected Patients.Predict It and Prevent It. 2015
In this downloadable slideset, Priscilla Y. Hsue, MD, and David A. Wohl, MD, discuss data on using traditional and newer markers and modalities to predict and prevent cardiovascular disease in HIV-infected patients.
Format: Microsoft PowerPoint (.ppt)
File size: 3.21 MB
Date posted: 7/16/2015
Wesley Campbell, M.D., of U.S. Navy Medicine, presents "Neurocognitive Changes in Newly Diagnosed Patient with Low CD4: Implications for Prognosis and Employment"
HIV Alert:ART Considerations for Aging Patients.2018hivlifeinfo
In this downloadable slideset, Eric S. Daar, MD, and David A. Wohl, MD, provide expert recommendations for older patients with HIV, both in terms of ART selection and general management.
Format: Microsoft PowerPoint (.ppt)
File size: 545 KB
Date posted: 2/12/2018
Immune Based Therapies for HIV Richard Trauger, phdSearch For A Cure
Presentation on Immune Based Therapies and their implications for HIV treatment presented at the Fenway Health Center, Boston, MA for the public education conference An End To AIDS - How A State Bill Can Change Everything conducted by SearchForACure.org, the Fenway Health
Center, and the MA Dept. of Public Health
Here is an article about why HIV/AIDS should still be on our radar: http://norwalk.patch.com/groups/zeena-nackerdiens-blog/p/why-hivaids-should-matter
The slide deck contains some of the latest info in the search for a durable cure.
Katherine Promer Flores, MD (she/her)
Staff Physician
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California San Diego
Daniel Lee, MD
Clinical Professor of Medicine
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Leandro Mena, MD, MPH
Chair and Professor of Population Health Science
Department of Population Health Science
University of Mississippi Medical Center
Maile Young Karris, MD
Associate Professor
Co-Director San Diego Center for AIDS Research Clinical Investigations Core
Divisions of Infectious Diseases & Global Public Health and Geriatrics & Gerontology
Department of Medicine
University of California San Diego
Edward Cachay, MD, MAS
Professor of Medicine
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Gabriel Wagner, MD
Associate Clinical Professor
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Jocelyn Keehner, MD
Infectious Disease Fellow
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Richard Garfein, PhD, MPH
Professor
Herbert Wertheim School of Public Health and Human Longevity Science
Adjunct Professor
Division of Infectious Disease and Global Public Health
Department of Medicine
University of California, San Diego
Laura Bamford, MD, MSCE
Associate Professor of Medicine
Medical Director, Owen Clinic
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California, San Diego
Davey Smith, MD, MAS
Professor of Medicine
Chief, Division of Infectious Diseases and Global Public Health
Co-Director, San Diego Center for AIDS Research (CFAR)
Department of Medicine
University of California, San Diego
Elliot Welford, MD
Infectious Diseases Fellow
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Darcy Wooten, MD
Assistant Professor of Medicine
Associate Program Director, Infectious Diseases Fellowship
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Amutha Rajagopal, MD
Associate Physician Diplomate
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
More from UC San Diego AntiViral Research Center (20)
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
CROI Update: What's New with HIV Associated Immune Activation
1. The UC San Diego AntiViral Research Center sponsors weekly
presentations by infectious disease clinicians, physicians and
researchers. The goal of these presentations is to provide the most
current research, clinical practices and trends in HIV, HBV, HCV, TB
and other infectious diseases of global significance.
The slides from the AIDS Clinical Rounds presentation that you are
about to view are intended for the educational purposes of our
audience. They may not be used for other purposes without the
presenter’s express permission.
AIDS CLINICAL ROUNDS
2. Maile Karris, MD
Check out Sharon Lewin’s CROI 2013 webcast “ART and
Inflammation: Implications for the Approach to Care in 2013”
Original presentation:Tuesday March 5
Update from CROI 2013: HIV and
Immune Activation
3. What we will cover today
HIV Immune Activation
Why does it matter?
Can we do anything about it?
What about ART choices?
4. HIV Immune Activation?
HIV is characterized not only by immunodeficiency
but also by generalized persistent immune activation
Adaptive immunity (T cells, B cells)
Innate immunity (APCs, NKs)
Coagulation cascade
5. Why does it matter?
HIV infected persons experience more non-AIDS
associated events than HIV negative peers
Even after adjustments for age,ART exposure and traditional
risk factors
6. The main contributor to this observed increase risk
of non-AIDS events is thought to be persistent
immune activation
7. Soluble Markers of Inflammation & Coagulation,
but not T-Cell Activation, Predict Non-AIDS-
Defining Events During Suppressive ART
TenorioA, Zheng E, Bosch R, Deeks S, Rodriguez B, Krishnan S, Hunt P,Wilson C, Leerman M,
LandayA andACTG
Define the associations between IA with NAE
- accounting for ART and traditional RF
Case-control study of ALLRT cohort
ART naïve + HIV-1 RNA < 400 c/mL at week 48 ofART
+ Maintained HIV RNA < 400 c/mL
143 Cases and 315 Controls
Evaluated multiple markers of IA
T cell, and soluble markers 790
8. Higher IL-6, sCD14, sTNFr-I, sRNFR-II, and D-dimer were
associated with non-AIDS related morbidity or death
Associations were present prior to ART and persisted despiteART
Independent of traditional risk factors
Controls had higher median CD4+ T cell change one year on
ART than cases
A greater CD4+T cell change at one year was associated with
decreased risk for non-AIDS related outcome
Association of biomarkers and odds of SNAE
BASELINE ONE-YEAR PRE-EVENT
9. Combined Effect of IL-6 and D-dimer on the
risk of Serious Non-AIDS Conditions
Grund B, Baker J, Deeks S,Wolfson J,Wentworth D, Cozzi-Lepri A, Cohen C, Phillips A,
Lundgren J, Neaton J
Estimate the joint associations of IL-6 and D-
dimer with the risk of composite outcome of
SNA/death in treated suppressed pts
The predictive utility of using IL-6 and/or D-dimer
as a markers for future candidate drugs
Data from ESPRIT, SILCAAT, SMART
SESSION 10 ORAL ABSTRACTS #60
12. The IL-6 & d-dimer score could be used to
compare drugs with different mechanisms of
action (targeting IL-6, d-dimer, or both) for their
potential to reduce SNA/death
13. Monocyte Activation but not T cell Activation
Predicts Progession of Coronary Artery Calcium
in a Contemporary HIV Cohort (SUN)
Baker J
Identify cellular phenotypes reflecting IA that
predict accelerated coronary atherosclerosis
SUN study – prospective observational cohort
Naïve to ART or solely exposed to combination ART
Measured changes in CAC scores
ImmunophenotypedT cells and monocytes
SESSION 10 ORAL ABSTRACTS #66LB
14. Short time progression in Coronary atherosclerosis was
predicted by higher frequence of CD16+ monocytes
No associations present between CD4 or CD8T ell
phenotypes or immune depletion (total CD4T cell count)
Suggest ongoing innate IA may be a proximal mechanism and
subsequently possible therapeutic target in the pathogenesis
of HIV-related CAD
15.
16. The Impact of Age on the Prognostic Capacity of
CD8+ T-cell Activation during Suppressive ART
Lok J, Hunt P, Collier A, Benson C,Witt M, LuqueA, Deeks S, Bosh R.
Evaluate the impact of age, CD4 and CD8T-cell
activation on AIDS and NAE during
suppressive ART
1025ART naïve who were had HIV RNA < 200 cp/mL at
1 yr ofART
CD8+T cell activation (% CD38+HLA-DR+), CD4
counts, and age as predictors of NAE or AIDS 2-5 years
fromART
793
17. 94 subjects had events in years 2-5
12AIDS defining 82 nonAIDS defining = 13% probability
18. Older HIV infected persons are at significantly icnreased
risk of clinical events compared to younger subjects
19. What Causes HIV IA?
Immune
Activation
Low level
HIV
replication
Microbial
Translocation
Co-infection with
other viruses
- Incomplete drug
penetration into
compartments
- Suboptimal HAART
- Intermittent activation of
latently infectedT cells
Replication induced by
- HIV
- Immunosuppression
- Cytokines
-Loss of GALT CD4T cells
-Local cytokine release damages gut epithelials
-Collagen deposition
20. What can we do about it?
Treating immune activation
Immunosuppressive drugs
Ongoing HIV Replication - treatment
intensification
Co-infections – treatment of co-infections
Microbial translocation
Drugs that specifically impact known biomarkers
associated with NAE (d-dimer, IL-6, sCD14 etc)
21. Statin Use in HIV
Known to reduce CV and plaque regression
Decreased inflammation (CRP)
Decreased pro-inflammatory monocyte subsets in
animal models
Significantly beneficial survival ratio in persons
on statins with HIV (longitudinal cohort study)
But statins haveAE
22. The Effect of Statins on Immune Activation and
Inflammation in HIV-Infected Subjects on ART
McComsey G, JiangY, Debanne S, Clagett B, Robinson J, Labbato D, Storer N, Lederman M,
Funderburg N.
To assess the effect of 24 weeks of statin on
systemic and vascular inflammation and in
monocyte and lymphocyte IA in HIV + on ART
146 participants enrolled in a RCCT of rosuvastatin
StableART with HIV-1 RNA < 1,000 copies/mL
CD8+CD38+HLA-DR+ > 19% or hsCRP > 2 mg/L
LDL < 130 mg/dL
Measured soluble IA markers, vascular inflammation,
monocyte and lymphocyte activation markers 186LB
23. Changes in the proportion of CD14dim16+TF+ and in levels of sCD14
and lipoprotein associated phospholipase A2
CD14dimcd16+TF+
sCD14+
Lp-PLA2
24. Impact of Statin Exposure on Mortality and Non-
AIDS Complications in HIV Patients on HAART
Drechsler H, Zhang S, Maalouf N, Cutrell J,Tebas P, Bedimo R.
Evaluate the impact of cumulative exposure of
statins on death or NAE in a clinical cohort
VA Clinical Case Registry to find persons on HAART
< 14 days (1995-2009)
Analyzed all persons on HAART (n = 25,884) and those
who were suppressed within 18 weeks (n = 15,936)
Looked at occurrence of death, CVA, MI, malignancy,
fragility fractures
765
25. Cumulative
exposure to
statins was
associated with a
signficant
reduction in all-
cause mortality
in virologically
suppressed
persons
The effect size
was larger with
exposure to
atorvastatin and
rosuvastatin
26. Does ART matter?
ART regimens historically evaluated on their
ability to suppress viremia and CD4+ T-cell
recovery
ART regimens are also evaluated by their
toxicities
So are certain ART regimens “better” at
decreasing HIV associated IA?
27. cART-Induced Immunological Function Restoration
is Independent of the cART Regimen and is not
Correlated with the Extent of CD4 Gains
Rallon N,Torres B, Diaz Al,Alos L, Martinez E, LeonA, Gatell J, SorianoV, Garcia F, Benito J.
Assess the impact of LPV/r vs EFV on parameters
of immune function in a RCCT
50 naïve participants randomized to LPV/r or EFV
withTDF/FTC , 22 underwent evaluation of immune
parameters
Evaluated persons at baseline and week 48 for CD4 and
CD8 subsets, activation, recent thymic emigration,
senescence, exhaustion and apoptosis
310
28. The use of either LPV/r or EFV did not alter levels of
cellular IA
It is unclear if the differential changes that were
observed are of clinical significance
29. Early Changes in Adhesion Molecules Expression
and Endothelial Function in Patients Initiating
ART with Atazanavir or Lopinavir
BanderaA,Trabattoni D, Squillace N, MuscatelloA, Calascibetta F, MaolbertiA, Giannattasio C,
MarcandalliV, Clerici M, Gori A.
Does treatment with ATZ versus KAL
differentially impact immune or metabolic
parameters
Prospective randomized study of 30 naïve participants
200 < CD4 < 500/uL
No CVD,OI or tx with immunomodulant agents
Evaluated clinical, lipid, and immune parameters and
indices of endothelial structure, function and arterial
stiffness 752
30. No difference between study arms was observed for
Changes in proportions ofT cell subsets
Decreases in cell surface activation markers onT
cells and monocytes
Did observe that persons on atazanavir demonstrated a
“particularly strong” increase in the expression of
CD11a on CD4+T-cells
31. ART with either atazanavir or lopinavir did not
impact intima mediat thickness, or pulse wave
velocity by week 24
However there was a trend to decreased arterial
diameter in the atazanavir arm compared to
lopinavir
32. Soluble CD14 Declines in Virologically Suppressed
Women Switching from PI or NNRTI to Raltegravir:
The Women, Integrase and Fat Accumulation Trial
794
Lake J, McComsey G, HulganT,Wanke C, MangiliA,Walmsley S, Boger M, Stramotas S, Currier J.
Describe changes in markers of microbial
translocation and monocyte activation during
ART regimen switches
48 week study HIV women who switch to RAL at
week 0 or week 24
with central adiposity HIVVL < 50 copies/mL
On NNTRI or PI based regimen
Evaluated sCD14, sCD164,TNFRII, I-FABP,TNF-a
34. Other changes observed include significant increases in
expression ofTNF-alpha andTNFRII
35. Conclusions on HIV IA
Why does it matter?
SNAE are associated with abnormalities in innate
immune markers
Steps are being made to attempt to come up with a
marker or score that in the future may assist
clinicians in identifying which of their patients are
at most risk for SNAE
As our patients are living longer, we need to be
more vigilant about prevention of known risk
factors for SNAE
36. Conclusions on HIV IA
Can we do anything about it?
Support is growing for the use of statins in our
population but the recommendation is not there
yet
Stay tuned for CROI 2014 and beyond
37. Conclusions on HIV IA
What aboutART choices?
ART choices may impact IA, but more
extensive studies are necessary
38. CROI 2013 PODCASTS
MONDAY
- Themed Discussion 16: Statin Use and HIV: How Sweet Is It?
- Oral Abstracts Session 19: CVD and other Non-AIDS Events
Epidemiology and Pathogenesis
TUESDAY
- Symposia: Opportunities andThreats toART Success
WEDNESDAY
-Themed Discussion 49: Inflammatory Biomarkers,
Microparticles and Clinical Outcomes